|
1
|
Marino P, Pampallona S, Preatoni A,
Cantoni A and Invernizzi F: Chemotherapy vs supportive care in
advanced non-small-cell lung cancer. Results of a meta-analysis of
the literature. Chest. 106:861–865. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
No authors listed. Chemotherapy in
non-small cell lung cancer: a meta-analysis using updated data on
individual patients from 52 randomized clinical trials. Non-small
Cell Lung Cancer Collaborative Group. BMJ. 311:899–909. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bonomi P, Kim K, Fairclough D, Cella D,
Kugler J, Rowinsky E, et al: Comparison of survival and quality of
life in advanced non-small-cell lung cancer patients treated with
two dose levels of paclitaxel combined with cisplatin versus
etoposide with cisplatin: results of an Eastern Cooperative
Oncology Group trial. J Clin Oncol. 18:623–631. 2000.
|
|
4
|
Le Chevalier T, Brisgand D, Douillard JY,
Pujol JL, Alberola V, Monnier A, et al: Randomized study of
vinorelbine and cisplatin versus vindesine and cisplatin versus
vinorelbine alone in advanced non-small-cell lung cancer: results
of a European multicenter trial including 612 patients. J Clin
Oncol. 12:360–367. 1994.PubMed/NCBI
|
|
5
|
Metro G, Cappuzzo F, Finocchiaro G, Toschi
L and Crinò L: Development of gemcitabine in non-small cell lung
cancer: the Italian contribution. Ann Oncol. 17:37–46. 2006.
View Article : Google Scholar
|
|
6
|
Bergman AM, Ruiz van Haperen VW, Veerman
G, Kuiper CM and Peters GJ: Synergistic interaction between
cisplatin and gemcitabine in vitro. Clin Cancer Res. 2:521–530.
1996.PubMed/NCBI
|
|
7
|
Lippe P, Tummarello D, Monterubbianesi MC,
Silva RR, Giuliodori L, Mari D, et al: Weekly gemcitabine and
cisplatin in advanced non-small-cell lung cancer: a phase II study.
Ann Oncol. 10:217–221. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abratt RP, Bezwoda WR, Goedhals L and
Hacking DJ: Weekly gemcitabine with monthly cisplatin: effective
chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol.
15:744–749. 1997.PubMed/NCBI
|
|
9
|
Einhorn LH: Phase II trial of gemcitabine
plus cisplatin in non-small cell lung cancer: a Hoosier Oncology
Group study. Semin Oncol. 24:S824–S826. 1997.PubMed/NCBI
|
|
10
|
Crinò L, Scagliotti G, Marangolo M, Figoli
F, Clerici M, De Marinis F, et al: Cisplatin-gemcitabine
combination in advanced non-small-cell lung cancer: a phase II
study. J Clin Oncol. 15:297–303. 1997.
|
|
11
|
Chen SC, Lin MC, Chang JW, Wang SW, Lee CH
and Tsao TC: Phase II study of regimen of gemcitabine and cisplatin
in advanced non-small cell lung cancer. Jpn J Clin Oncol.
30:494–498. 2000. View Article : Google Scholar
|
|
12
|
Le Chevalier T, Scagliotti G, Natale R,
Danson S, Rosell R, Stahel R, et al: Efficacy of gemcitabine plus
platinum chemotherapy compared with other platinum containing
regimens in advanced non-small-cell lung cancer: a meta-analysis of
survival outcomes. Lung Cancer. 47:69–80. 2005.PubMed/NCBI
|
|
13
|
Crinò L, Scagliotti GV, Ricci S, De
Marinis F, Rinaldi M, Gridelli C, et al: Gemcitabine and cisplatin
versus mitomycin, ifosfamide, and cisplatin in advanced
non-small-cell lung cancer: A randomized phase III study of the
Italian Lung Cancer Project. J Clin Oncol. 17:3522–3530.
1999.PubMed/NCBI
|
|
14
|
Sandler AB, Nemunaitis J, Denham C, von
Pawel J, Cormier Y, Gatzemeier U, et al: Phase III trial of
gemcitabine plus cisplatin versus cisplatin alone in patients with
locally advanced or meta-static non-small-cell lung cancer. J Clin
Oncol. 18:122–130. 2000.PubMed/NCBI
|
|
15
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, et al: Comparison of four
chemotherapy regimens for advanced non-small-cell lung cancer. N
Engl J Med. 346:92–98. 2002. View Article : Google Scholar
|
|
16
|
Belani CP: Docetaxel in combination with
platinums in patients with advanced non-small-cell lung cancer.
Oncology. 11:42–45. 1997.PubMed/NCBI
|
|
17
|
Fossella F, Pereira JR, von Pawel J,
Pluzanska A, Gorbounova V, Kaukel E, et al: Randomized,
multinational, phase III study of docetaxel plus platinum
combinations versus vinorelbine plus cisplatin for advanced
non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol.
21:3016–3024. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kubota K, Watanabe K, Kunitoh H, Noda K,
Ichinose Y, Katakami N, et al: Phase III randomized trial of
docetaxel plus cisplatin versus vindesine plus cisplatin in
patients with stage IV non-small-cell lung cancer: the Japanese
Taxotere Lung Cancer Study Group. J Clin Oncol. 22:254–261. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sobin LH and Fleming ID: TNM
Classification of Malignant Tumors, fifth edition (1997). Union
Internationale Contre le Cancer and the American Joint Committee on
Cancer. Cancer. 80:1803–1804. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tabata M, Kozuki T, Ueoka H, Nicolella GP,
Natale M, Pacilio C, et al: A triplet chemotherapy with cisplatin,
docetaxel and gemcitabine in patients with advanced non-small-cell
lung cancer: a phase I/II study. Cancer Chemother Pharmacol.
60:53–59. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Frasci G, Panza N, Comella P, Manzione L,
De Cataldis G, Cioffi R, et al: Cisplatin, gemcitabine and
vinorelbine in locally advanced or metastatic non-small-cell lung
cancer: a phase I study. Ann Oncol. 8:1045–1048. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Comella P, Frasci G, Panza N, Soria JC, Le
Chevalier T and Pignon P: Randomized trial comparing cisplatin,
gemcitabine, and vinorelbine with either cisplatin and gemcitabine
or cisplatin and vinorelbine in advanced non-small-cell lung
cancer: interim analysis of a phase III trial of the Southern Italy
Cooperative Oncology Group. J Clin Oncol. 18:1451–1457. 2000.
|
|
23
|
Delbaldo C, Michiels S, Syz N, Soria JC,
Le Chevalier T and Pignon JP: Benefits of adding a drug to a
single-agent or a 2-agent chemotherapy regimen in advanced
non-small-cell lung cancer: a meta-analysis. JAMA. 292:470–484.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Azim HA Jr, Elattar I, Loberiza FR Jr,
Azim H, Mok T and Ganti AK: Third generation triplet cytotoxic
chemotherapy in advanced non-small cell lung cancer: a systematic
overview. Lung Cancer. 64:194–198. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li JL, Zhang XR, Liu JW, Fujiwara Y,
Toyooka S and Umemura S: Phase I/II clinical trial of weekly
administration of docetaxel plus cisplatin for advanced non-small
cell lung cancer. Zhonghua Zhong Liu Za Zhi. 28:309–312. 2006.(In
Chinese).
|
|
26
|
Fujimoto N, Kiura K, Takigawa N, Kiura K,
Harita S, Tada A, et al: Triplet chemotherapy with cisplatin,
docetaxel, and irinotecan for patients with recurrent or refractory
non-small cell lung cancer. Acta Med Okayama. 64:33–37.
2010.PubMed/NCBI
|
